Revance Adds Life Sciences Audit Executive Chris Nolet to Board of Directors
July 17 2019 - 8:00AM
Business Wire
- Nolet will serve as Chair of the Audit
Committee -
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology
company developing a new category of high-performance
neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced the appointment of Chris Nolet to the
company’s Board of Directors. Mr. Nolet brings deep experience as a
long-time audit partner and business advisor in the Life Sciences
industry, and will provide strong leadership as he also assumes the
role of Chair of the Revance Audit Committee, planned for
mid-August.
“Chris Nolet brings an extraordinary record of industry-shaping
consultation to the Revance Board of Directors,” said Dan Browne,
President and Chief Executive Officer of Revance. “Chris’s
leadership roles with Ernst & Young (EY) Life Sciences Industry
Group and the California Life Sciences Industry Association (CLSA)
among others, bring invaluable economic, operational, and policy
expertise to the company. As Chair of the Audit Committee, he will
provide valuable oversight of our corporate accounting and
financial reporting processes, internal controls, financial
reporting and audit functions, as we our progress towards
commercial company status.”
Mr. Nolet is the former West Region Life Sciences Industry
Leader & Partner at EY, retiring in June of 2019 after more
than 38 years in the profession. In addition to serving clients,
his responsibilities included leading West Region EY Life Sciences
Industry Group, and serving as a member of the Global EY Life
Sciences Executive Leadership Group, which established policies and
operating strategies for EY Life Sciences practice worldwide. He
currently serves on both the Executive Committee and Audit
Committee (Chair) of CLSA, and is a former member of the Finance
& Investment Committee and Emerging Companies Section of the
Biotechnology Innovation Organization. Prior to joining EY, Mr.
Nolet was a partner at PricewaterhouseCoopers where he led the
Life Sciences practice in the western U.S. He has a B.S. in
Accounting from San Diego State University and is a Certified
Public Accountant in California.
“I have been very fortunate to work with the full range of life
sciences companies, from rapidly growing venture-capital backed
startups to Fortune 100 companies, and understand the underpinnings
of a successful commercial biotech business,” said Mr. Nolet. “I am
elated to be a part of the Revance board as the company prepares to
meaningfully transform patient experiences and disrupt the $4.5
billion global neuromodulator industry with its innovative
science.”
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company focused on
developing transformative neuromodulators to address a broad
spectrum of aesthetic and therapeutic conditions. Revance’s lead
product candidate, DaxibotulinumtoxinA for Injection (DAXI),
utilizes a unique proprietary peptide excipient technology combined
with highly purified botulinum toxin type A to produce a novel,
long-acting neuromodulator. In aesthetics, Revance successfully
completed its Phase 3 program for DAXI in glabellar (frown) lines
and is currently pursuing U.S. regulatory approval in 2020, while
also running two separate Phase 2 studies in forehead lines and
lateral canthal lines (crow’s feet). In therapeutics, DAXI is being
studied in three indications, including a Phase 3 trial in cervical
dystonia, a Phase 2 trial in adult upper limb spasticity, and a
Phase 2 trial in plantar fasciitis, with plans to also study
migraine. Beyond DAXI, Revance also has begun development of a
biosimilar to BOTOX®, which would compete in the existing
short-acting neuromodulator marketplace. More information on
Revance may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc. BOTOX® is a registered
trademark of Allergan, Inc.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements related to the process and timing of, and
ability to complete, current and anticipated future clinical
development of our investigational drug product candidates, the
initiation, design, timing and results of our clinical studies
statements about our business and brand strategy, including our
potential products, timeline and other goals and market for our
anticipated products, plans and prospects; including our plans and
timing and potential commercialization, with respect to our product
candidates; statements about potential benefits of our drug product
candidates and our excipient peptide and other technologies.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties include, but
are not limited to: the outcome, cost, and timing of our product
development activities and clinical trials; the uncertain clinical
development process, including the risk that clinical trials may
not have an effective design or generate positive results; our
ability to obtain and maintain regulatory approval of our drug
product candidates; our ability to obtain funding for our
operations; our plans to research, develop, and commercialize our
drug product candidates; our ability to achieve market acceptance
of our drug product candidates; unanticipated costs or delays in
research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the
size and growth potential of the markets for our drug product
candidates; our ability to successfully commercialize our drug
product candidates and the timing of commercialization activities;
the rate and degree of market acceptance of our drug product
candidates; our ability to develop sales and marketing
capabilities; the accuracy of our estimates regarding expenses,
future revenues, capital requirements and needs for financing; our
ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks.
Detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange Commission (the
"SEC"), including factors described in the section entitled "Risk
Factors" of our of our quarterly report on Form 10-Q filed May 9,
2019. These forward-looking statements speak only as of the date
hereof. Revance disclaims any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190717005203/en/
INVESTORS Revance Therapeutics, Inc.: Jeanie Herbert,
714-325-3584 jherbert@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
MEDIA General Media: Y&R: Jenifer Slaw 347-971-0906
jenifer.slaw@YR.com or Trade Media: Nadine Tosk, 504-453-8344
nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024